China Pharma Holdings, Inc. (CPHI) Financial Ratios
23 years of historical data (2002–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
N/A
—
5yr avg: 17290.91
30Y Low66.6·High92.7
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.19
↓-98% vs avg
5yr avg: 77.22
30Y Low3.1·High185.0
ROE
↓
-62.3%
-14% vs avg
5yr avg: -54.7%
30Y Low-105%·High65%
Debt/EBITDA
↑
N/A
—
5yr avg: 885.03
30Y Low0.0·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CPHI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
China Pharma Holdings, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $41M | $64M | $252M | $1.1B | $1.0B | $546M | $594M | $405M | $600M | $362M |
| Enterprise Value | $12M | $44M | $67M | $259M | $1.1B | $1.0B | $552M | $600M | $413M | $608M | $373M |
| P/E Ratio → | -1.95 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.03 | 8.98 | 9.15 | 31.14 | 115.44 | 94.62 | 50.00 | 48.15 | 30.65 | 38.51 | 17.79 |
| P/B Ratio | 1.19 | 5.25 | 8.60 | 58.82 | 184.97 | 128.46 | 59.12 | 19.66 | 9.40 | 10.18 | 4.98 |
| P/FCF | — | — | — | — | — | — | 1156.38 | 492.34 | 574.70 | 221.91 | 351.34 |
| P/OCF | — | — | — | — | — | — | 897.85 | 472.31 | 481.46 | 207.09 | 108.09 |
P/E links to full P/E history page with 30-year chart
CPHI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.64 | 9.60 | 31.97 | 116.23 | 95.22 | 50.51 | 48.68 | 31.25 | 39.06 | 18.32 |
| EV / EBITDA | — | — | 36715.78 | — | 4930.39 | 10226.56 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 1168.13 | 497.84 | 585.92 | 225.06 | 361.72 |
CPHI Profitability
Margins and return-on-capital ratios measuring operating efficiency
China Pharma Holdings, Inc. earns an operating margin of -101.3%. Operating margins have compressed from -43.8% to -101.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -62.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -43.8% | -43.8% | -4.0% | -6.1% | 3.6% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% | 7.2% |
| Operating Margin | -101.3% | -101.3% | -39.2% | -43.8% | -29.7% | -23.7% | -31.0% | -32.2% | -34.0% | -26.9% | -69.8% |
| Net Profit Margin | -104.6% | -104.6% | -43.9% | -49.0% | -35.3% | -26.4% | -189.5% | -87.2% | -145.9% | -59.0% | -75.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.3% | -62.3% | -52.4% | -77.1% | -48.5% | -33.3% | -105.0% | -29.3% | -37.8% | -14.0% | -17.2% |
| ROA | -30.2% | -30.2% | -18.0% | -19.7% | -15.5% | -13.2% | -61.2% | -20.4% | -27.8% | -10.5% | -13.4% |
| ROIC | -32.2% | -32.2% | -19.0% | -21.6% | -15.3% | -13.2% | -9.9% | -6.8% | -5.7% | -4.2% | -10.5% |
| ROCE | -47.0% | -47.0% | -37.5% | -41.3% | -26.2% | -23.5% | -14.3% | -9.2% | -7.6% | -5.5% | -14.0% |
CPHI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $3M ($4M total debt minus $626879 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.46 | 0.46 | 0.62 | 2.04 | 2.08 | 0.93 | 0.72 | 0.26 | 0.23 | 0.19 | 0.23 |
| Debt / EBITDA | — | — | 2526.73 | — | 54.94 | 73.42 | — | — | — | — | — |
| Net Debt / Equity | — | 0.38 | 0.43 | 1.57 | 1.27 | 0.81 | 0.60 | 0.22 | 0.18 | 0.14 | 0.15 |
| Net Debt / EBITDA | — | — | 1750.37 | — | 33.56 | 63.95 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | 11.74 | 5.50 | 11.21 | 3.15 | 10.38 |
| Interest Coverage | -29.77 | -29.77 | -8.25 | -8.17 | -5.28 | -8.76 | -10.54 | -8.79 | -8.34 | -4.94 | -12.18 |
CPHI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.65x is below 1.0, meaning current liabilities exceed current assets. The quick ratio of 0.20x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 0.47x to 0.65x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.65 | 0.65 | 0.88 | 0.47 | 0.86 | 0.47 | 0.56 | 0.87 | 1.33 | 1.68 | 1.95 |
| Quick Ratio | 0.20 | 0.20 | 0.33 | 0.24 | 0.55 | 0.14 | 0.20 | 0.37 | 0.64 | 0.98 | 1.20 |
| Cash Ratio | 0.12 | 0.12 | 0.21 | 0.16 | 0.46 | 0.08 | 0.11 | 0.12 | 0.22 | 0.26 | 0.49 |
| Asset Turnover | — | 0.30 | 0.43 | 0.46 | 0.43 | 0.51 | 0.49 | 0.27 | 0.22 | 0.20 | 0.21 |
| Inventory Turnover | 2.87 | 2.87 | 1.95 | 2.92 | 2.78 | 2.41 | 2.63 | 2.05 | 1.68 | 1.69 | 1.95 |
| Days Sales Outstanding | — | 22.65 | 37.91 | 20.92 | 31.62 | 17.79 | 22.79 | 32.18 | 67.85 | 99.02 | 98.01 |
CPHI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
China Pharma Holdings, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 0.1% | 0.2% | 0.2% | 0.5% | 0.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $17M | $11M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M |
Peer Comparison
Compare CPHI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CPHIYou | $9M | -1.9 | — | — | -43.8% | -101.3% | -62.3% | -32.2% | — |
 CHNR | $42M | -88.7 | — | — | — | — | -0.0% | -0.0% | — |
 CNET | $2M | -0.4 | — | — | 2.9% | -24.3% | -75.4% | -64.7% | — |
 SGBX | $32963 | -0.0 | — | — | -4.9% | -195.0% | — | -62569.3% | — |
 SIGA | $339M | 14.3 | -6387033.1 | 7.0 | 68.0% | 25.1% | 0.0% | 0.0% | 0.0 |
 HROW | $1B | -278.9 | — | — | 75.1% | 11.2% | -8.5% | 9.5% | — |
 LXRX | $712M | -12.0 | — | — | 99.4% | -98.2% | -39.7% | -22.7% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $44B | 28.7 | 16.0 | 23.6 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 21.8 | 14.1 | 18.5 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
See CPHI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPHI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPHI vs CHNR
Side-by-side business, growth, and profitability comparison vs China Natural Resources, Inc..
Start ComparisonCPHI — Frequently Asked Questions
Quick answers to the most common questions about buying CPHI stock.
What is China Pharma Holdings, Inc.'s P/E ratio?
China Pharma Holdings, Inc.'s current P/E ratio is -1.9x. The historical average is 100.3x.
What is China Pharma Holdings, Inc.'s ROE?
China Pharma Holdings, Inc.'s return on equity (ROE) is -62.3%. The historical average is -12.7%.
Is CPHI stock overvalued?
Based on historical data, China Pharma Holdings, Inc. is trading at a P/E of -1.9x. Compare with industry peers and growth rates for a complete picture.
What are China Pharma Holdings, Inc.'s profit margins?
China Pharma Holdings, Inc. has -43.8% gross margin and -101.3% operating margin.